JPWO2020178638A5 - - Google Patents

Info

Publication number

JPWO2020178638A5

JPWO2020178638A5 JP2021552586A JP2021552586A JPWO2020178638A5 JP WO2020178638 A5 JPWO2020178638 A5 JP WO2020178638A5 JP 2021552586 A JP2021552586 A JP 2021552586A JP 2021552586 A JP2021552586 A JP 2021552586A JP WO2020178638 A5 JPWO2020178638 A5 JP WO2020178638A5

Authority

JP

Japan

Prior art keywords

composition

patient

stage

antibody

seq

Prior art date

2023-03-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 76
• 208000023761 AL amyloidosis Diseases 0.000 claims description 44
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 44
• 239000000203 mixture Substances 0.000 claims description 43
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 21
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 21
• 102000054727 Serum Amyloid A Human genes 0.000 claims description 13
• 108700028909 Serum Amyloid A Proteins 0.000 claims description 13
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
• 108060003951 Immunoglobulin Proteins 0.000 claims description 6
• 102000018358 immunoglobulin Human genes 0.000 claims description 6
• 206010049993 Cardiac death Diseases 0.000 claims description 5
• 206010011906 Death Diseases 0.000 claims description 5
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
• 229960001467 bortezomib Drugs 0.000 claims description 2
• 230000008859 change Effects 0.000 claims description 2
• 229960004397 cyclophosphamide Drugs 0.000 claims description 2
• 229960002204 daratumumab Drugs 0.000 claims description 2
• 229960003957 dexamethasone Drugs 0.000 claims description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
• 229960004679 doxorubicin Drugs 0.000 claims description 2
• 229960003722 doxycycline Drugs 0.000 claims description 2
• XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
• 230000006872 improvement Effects 0.000 claims description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
• 229960004942 lenalidomide Drugs 0.000 claims description 2
• 229960001924 melphalan Drugs 0.000 claims description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• 238000002054 transplantation Methods 0.000 claims description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
• 206010002022 amyloidosis Diseases 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000007407 health benefit Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1